Primary Outcome Measures:
- leg blood flow response to insulin [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- insulin-stimulated leg glucose uptake [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- insulin-stimulated whole body glucose uptake [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- leg blood flow response to methacholine chloride [ Time Frame: 3 months ] [ Designated as safety issue: No ]
- leg blood flow response to L-NMMA [ Time Frame: 3 months ] [ Designated as safety issue: No ]
Intervention Details:
Drug: Losartan
Tablet, 100mg, once per day for 3 months
Recent studies suggesting an effect of cardiovascular therapies to prevent diabetes remain unexplained. We hypothesize that these therapies improve vascular endothelial function allowing improved actions of insulin in the vasculature, which comprise a significant portion of insulin's metabolic action. We therefore propose to measure insulin-mediated glucose disposal and insulin-mediated vasodilation before and after 12 weeks' therapy with Losartan (an angiotensin receptor blocker) or placebo, in a randomized design. Subjects will include 28 subjects with impaired glucose tolerance, which is generally accompanied by both insulin resistance and impaired vascular function. With this number of participants we have a 90% chance of showing a statistically significant and clinically meaningful effect of insulin on leg vascular resistance, and an even higher chance of showing a difference in insulin's metabolic effects. Exclusion criteria will include frank hypertension, diabetes, or hypercholesterolemia, and biochemical or other contraindications to losartan therapy. The primary endpoint for statistical analysis will be the invasive measure of insulin-stimulated endothelial function. We anticipate an improvement in both vascular and metabolic measures of insulin action following Losartan therapy but no change from untreated baseline following placebo.
Purpose
